Incidence of Diabetic Ketoacidosis in Dapagliflozin‐Treated Japanese Patients With Type 1 Diabetes Mellitus: An Observational Cohort Database Study
Pharmacoepidemiology and Drug Safety · 2026
DOI: 10.1002/pds.70294 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2026. Verfasst von Reiko Tamura und 6 weiteren Autor:innen. Beteiligte Einrichtung: Japan Patient Safety, AstraZeneca K.K., Osaka, Japan. Hauptthemen laut MEDLINE: Diabetic Ketoacidosis, Benzhydryl Compounds, Glucosides, Diabetes Mellitus, Type 1. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AstraZeneca.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Purpose
Diabetic ketoacidosis (DKA) is an important identified risk of treatment with the sodium‐glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin, particularly in patients with type 1 diabetes mellitus (T1DM). We evaluated the DKA incidence rate (IR) among dapagliflozin‐treated Japanese patients with T1DM receiving concomitant insulin.
Methods
This observational, cohort, post‐marketing study utilized data from the JMDC Payer database. All patients had T1DM and were prescribed insulin; the dapagliflozin group included dapagliflozin‐treated patients and the control group included SGLT2i nonusers. The study outcomes were DKA events (a composite of DKA resulting in hospitalization and/or death). Using a prevalent new‐user design, time‐stratified sequential propensity score (PS) matching was implemented.
Results
Between March 2019 and March 2021, 5886 insulin‐treated patients with T1DM were eligible, and 327/5886 patients newly received dapagliflozin. After up to 1:3 PS‐matching, 327 dapagliflozin‐treated patients and 980 matched controls were analyzed. The IRs (95% confidence interval) of DKA in the PS‐matched cohort were 1.54 per 100 person‐years (/100 PY; 0.42–3.95) and 1.14/100 PY (0.55–2.10) in the dapagliflozin and control groups, respectively, with a hazard ratio of 1.28 (0.40–4.09). The IRs in the unmatched cohort were 1.54/100 PY (0.42–3.95) and 0.97/100 PY (0.72–1.27) in the dapagliflozin and control groups, respectively.
Conclusion
DKA incidence in dapagliflozin‐treated T1DM patients was slightly higher than in SGLT2i nonusers. As the confidence intervals overlapped, these results did not suggest any meaningful differences or unexpected higher risk of DKA, consistent with previous reports in other countries.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Japan Patient Safety, AstraZeneca K.K., Osaka, Japan.
- Research & Development, AstraZeneca K.K., Osaka, Japan.
- Evidence Observational Research, AstraZeneca K.K., Osaka, Japan.
- Safety Epidemiology, AstraZeneca Ltd., Cambridge, UK.
- PEPI Consultancy Ltd., Southampton, UK.
- University of Hertfordshire, Hatfield, UK.
ORCID-Profile: Tomoko Kobayashi
Förderung
- AstraZeneca
Zitieren
APA
Tamura, R., Kim, H., Takumi, Y., Ishihara, M., Kobayashi, T., Layton, D., & Sakamoto, K. (2026). Incidence of Diabetic Ketoacidosis in Dapagliflozin‐Treated Japanese Patients With Type 1 Diabetes Mellitus: An Observational Cohort Database Study. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70294
Vancouver
Tamura R, Kim H, Takumi Y, Ishihara M, Kobayashi T, Layton D, et al. Incidence of Diabetic Ketoacidosis in Dapagliflozin‐Treated Japanese Patients With Type 1 Diabetes Mellitus: An Observational Cohort Database Study. Pharmacoepidemiology and Drug Safety. 2026. doi:10.1002/pds.70294
BibTeX
@article{Tamura2026,
author = {Tamura, Reiko and Kim, Hyosung and Takumi, Yuko and Ishihara, Miyo and Kobayashi, Tomoko and Layton, Deborah and Sakamoto, Kei},
title = {Incidence of Diabetic Ketoacidosis in Dapagliflozin‐Treated Japanese Patients With Type 1 Diabetes Mellitus: An Observational Cohort Database Study},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2026},
doi = {10.1002/pds.70294}
}
EUVIMED